Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the expression of genes responsible for energy metabolism, cellular development, and differentiation. Their crucial biological roles dictate the significance of PPAR-targeting synthetic ligands in medical research...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/20/5055 |
id |
doaj-d4da5c09add84b2b86c9b1679af68387 |
---|---|
record_format |
Article |
spelling |
doaj-d4da5c09add84b2b86c9b1679af683872020-11-24T22:10:24ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-10-012020505510.3390/ijms20205055ijms20205055Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical EvidenceHong Sheng Cheng0Wei Ren Tan1Zun Siong Low2Charlie Marvalim3Justin Yin Hao Lee4Nguan Soon Tan5School of Biological Sciences, Nanyang Technological University Singapore, 60 Nanyang Drive, Singapore 637551, SingaporeLee Kong Chian School of Medicine, Nanyang Technological University Singapore, 11 Mandalay Road, Singapore 308232, SingaporeLee Kong Chian School of Medicine, Nanyang Technological University Singapore, 11 Mandalay Road, Singapore 308232, SingaporeSchool of Biological Sciences, Nanyang Technological University Singapore, 60 Nanyang Drive, Singapore 637551, SingaporeLee Kong Chian School of Medicine, Nanyang Technological University Singapore, 11 Mandalay Road, Singapore 308232, SingaporeSchool of Biological Sciences, Nanyang Technological University Singapore, 60 Nanyang Drive, Singapore 637551, SingaporePeroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the expression of genes responsible for energy metabolism, cellular development, and differentiation. Their crucial biological roles dictate the significance of PPAR-targeting synthetic ligands in medical research and drug discovery. Clinical implications of PPAR agonists span across a wide range of health conditions, including metabolic diseases, chronic inflammatory diseases, infections, autoimmune diseases, neurological and psychiatric disorders, and malignancies. In this review we aim to consolidate existing clinical evidence of PPAR modulators, highlighting their clinical prospects and challenges. Findings from clinical trials revealed that different agonists of the same PPAR subtype could present different safety profiles and clinical outcomes in a disease-dependent manner. Pemafibrate, due to its high selectivity, is likely to replace other PPARα agonists for dyslipidemia and cardiovascular diseases. PPARγ agonist pioglitazone showed tremendous promises in many non-metabolic disorders like chronic kidney disease, depression, inflammation, and autoimmune diseases. The clinical niche of PPARβ/δ agonists is less well-explored. Interestingly, dual- or pan-PPAR agonists, namely chiglitazar, saroglitazar, elafibranor, and lanifibranor, are gaining momentum with their optimistic outcomes in many diseases including type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, and primary biliary cholangitis. Notably, the preclinical and clinical development for PPAR antagonists remains unacceptably deficient. We anticipate the future design of better PPAR modulators with minimal off-target effects, high selectivity, superior bioavailability, and pharmacokinetics. This will open new possibilities for PPAR ligands in medicine.https://www.mdpi.com/1422-0067/20/20/5055clinical trialsmetabolic syndrometype 2 diabetes mellituscancernon-alcoholic fatty liver diseasescardiovascular diseasesneurological disorders |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hong Sheng Cheng Wei Ren Tan Zun Siong Low Charlie Marvalim Justin Yin Hao Lee Nguan Soon Tan |
spellingShingle |
Hong Sheng Cheng Wei Ren Tan Zun Siong Low Charlie Marvalim Justin Yin Hao Lee Nguan Soon Tan Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence International Journal of Molecular Sciences clinical trials metabolic syndrome type 2 diabetes mellitus cancer non-alcoholic fatty liver diseases cardiovascular diseases neurological disorders |
author_facet |
Hong Sheng Cheng Wei Ren Tan Zun Siong Low Charlie Marvalim Justin Yin Hao Lee Nguan Soon Tan |
author_sort |
Hong Sheng Cheng |
title |
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence |
title_short |
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence |
title_full |
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence |
title_fullStr |
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence |
title_full_unstemmed |
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence |
title_sort |
exploration and development of ppar modulators in health and disease: an update of clinical evidence |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2019-10-01 |
description |
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the expression of genes responsible for energy metabolism, cellular development, and differentiation. Their crucial biological roles dictate the significance of PPAR-targeting synthetic ligands in medical research and drug discovery. Clinical implications of PPAR agonists span across a wide range of health conditions, including metabolic diseases, chronic inflammatory diseases, infections, autoimmune diseases, neurological and psychiatric disorders, and malignancies. In this review we aim to consolidate existing clinical evidence of PPAR modulators, highlighting their clinical prospects and challenges. Findings from clinical trials revealed that different agonists of the same PPAR subtype could present different safety profiles and clinical outcomes in a disease-dependent manner. Pemafibrate, due to its high selectivity, is likely to replace other PPARα agonists for dyslipidemia and cardiovascular diseases. PPARγ agonist pioglitazone showed tremendous promises in many non-metabolic disorders like chronic kidney disease, depression, inflammation, and autoimmune diseases. The clinical niche of PPARβ/δ agonists is less well-explored. Interestingly, dual- or pan-PPAR agonists, namely chiglitazar, saroglitazar, elafibranor, and lanifibranor, are gaining momentum with their optimistic outcomes in many diseases including type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, and primary biliary cholangitis. Notably, the preclinical and clinical development for PPAR antagonists remains unacceptably deficient. We anticipate the future design of better PPAR modulators with minimal off-target effects, high selectivity, superior bioavailability, and pharmacokinetics. This will open new possibilities for PPAR ligands in medicine. |
topic |
clinical trials metabolic syndrome type 2 diabetes mellitus cancer non-alcoholic fatty liver diseases cardiovascular diseases neurological disorders |
url |
https://www.mdpi.com/1422-0067/20/20/5055 |
work_keys_str_mv |
AT hongshengcheng explorationanddevelopmentofpparmodulatorsinhealthanddiseaseanupdateofclinicalevidence AT weirentan explorationanddevelopmentofpparmodulatorsinhealthanddiseaseanupdateofclinicalevidence AT zunsionglow explorationanddevelopmentofpparmodulatorsinhealthanddiseaseanupdateofclinicalevidence AT charliemarvalim explorationanddevelopmentofpparmodulatorsinhealthanddiseaseanupdateofclinicalevidence AT justinyinhaolee explorationanddevelopmentofpparmodulatorsinhealthanddiseaseanupdateofclinicalevidence AT nguansoontan explorationanddevelopmentofpparmodulatorsinhealthanddiseaseanupdateofclinicalevidence |
_version_ |
1725808421692768256 |